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Objective
Materials & Methods
The cohort of cancer patients are from the 
Lankenau Medical Center outside of Philadelphia, PA. 
The hospital sees ~1,100 cancer patients per year. 
Colorectal patients constitute 14.7% while 10.4% are 
lung cancer patients. Of the patients enrolled in this 
study, 84.4% are Caucasian, 14.0% are African-
American and 1.6% are Asian. 
Blood drawn from consented and chemotherapy 
naïve patients (N= 59) were tested for glutathione 
recycling capacity and normalized to total red cell 
numbers. Patients reported neuropathy using the 
Rotterdam Symptom Check List. Patient’s glutathione 
recycling capacities were correlated to self-reported 
neuropathy.
Glutathione, an antioxidant, plays an important 
role in red-ox homeostasis and the recycling of 
glutathione can be determined by the ChemoTox 
assay.4 The aim of this study was to determine if 
ChemoTox can provide clinicians with a blood assay 
to quantitate platinum-induced neuropathy.
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Introduction
Background
Chemotherapy-induced peripheral neuropathy 
(CIPN) is a disabling side effect of platinum-based 
chemotherapies like cis-, oxali- and carboplatin. 
These therapies cause bursts of reactive oxygen 
species (ROS), which can trigger structural changes 
in peripheral nerves including neuronopathy, 
axonopathy and/or myelinopathy. There is no 
effective CIPN prevention strategy and medications 
to alleviate neuropathy often lack efficacy and/or 
have unacceptable side-effects. 
The “stocking and glove” distribution of 
neuropathy is primarily due to the vulnerability of 
long nerves in the peripheral nervous system. A 
meta-analysis of 31 CIPN studies involving 4,179 
patients indicated CIPN in 48% of patients. Within 
the first month of completing chemotherapy, the 
prevalence of CIPN was 68.1%; after 6 months of 
completing chemotherapy, the prevalence of CIPN 
decreased to 30.0%.1 A separate study indicated 
colon cancer patients who received oxaliplatin-based 
adjuvant chemotherapy had numbness or tingling of 
hands and feet up to 6 years from starting 
treatment.2 Due to the high frequency of neuropathy, 
there is a need for a test that can help clinicians 
better guide therapy and prevent this detrimental 
outcome.3
Characteristics Patients (%)
Number of 
patients
Number of patients 59
Median age (range) 64 (24 – 91)
Female 47.5 28
Primary Tumor
Colorectal 55.9 33
Lung 44.0 26
Chemotherapy treatments
59
52.7 35
Oxaliplatin 52.5 31
Carboplatin 38.9 23
Cisplatin 8.47 5
42 of 59 patients stated they experienced 
neuropathy during chemotherapy. 21 high risk 
patients were identified as those who reported 
experiencing neuropathy as a “2”, or “quite a bit” on 
the Rotterdam Checklist. 19 of the 21 patients 
experienced increasing neuropathy within their first 
5 treatments. Select correlates above are patient-
reported neuropathy (0-3) in blue, and ChemoTox 
quantities (ng / ml plasma and 106 RBC) in red. 
• Taxane therapies, another culprit for causing 
CIPN via ROS, is a target population for future 
studies of ChemoTox efficacy.
• Platinum therapy as a treatment for breast 
cancer should be explored to see if systemic 
ROS provides a similar pattern to that of patients 
with lung and colon cancer.
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• 72.2% reported neuropathy during 
chemotherapy and 35.6% were recognized as 
high risk patients for  progressive CIPN. These 
outcomes, despite the small cohort size, are 
representative of larger studies.
• Patients LH12-015, LH12-018 and LH12-039
display trends that initially show decreased 
glutathione recycling capacities and remain low 
over time. This correlation detects a patient 
population that can be addressed earlier as to 
the direction of treatment.
• Patients LH12-026, LH12-027 and LH12-036 
illustrate a patient population that initially display 
adequate glutathione recycling capacity. 
However, the inability to maintain turnover 
during extended treatment cycles identifies the 
inverse correlation as a trend of concern. 
• Low glutathione recycling also has a corollary to 
an increased risk for chemotherapy induced 
nausea and vomiting (CINV). Among the 
patients shown in results, 5/6 patients reported 
some level of nausea, and 4/6 reported 
moderate to severe delayed nausea.4
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